{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMR101+%28VASCEPA%2C+icosapent+ethyl%29",
    "query": {
      "intervention": "AMR101 (VASCEPA, icosapent ethyl)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMR101+%28VASCEPA%2C+icosapent+ethyl%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T09:53:33.738Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01154985",
      "title": "Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        },
        {
          "name": "EPA-E 300 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mochida Pharmaceutical Company, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2010-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-20",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154985"
    },
    {
      "nct_id": "NCT03661047",
      "title": "OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "AMR101 (VASCEPA, icosapent ethyl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-11-30",
      "completion_date": "2021-11-30",
      "has_results": false,
      "last_update_posted_date": "2021-11-17",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03661047"
    },
    {
      "nct_id": "NCT00069784",
      "title": "The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "omega-3 polyunsaturated fatty acids (PUFA)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "reusable pen device for insulin injection",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12537,
      "start_date": "2003-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069784"
    },
    {
      "nct_id": "NCT01492361",
      "title": "A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "AMR101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Statin therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 8179,
      "start_date": "2011-11",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492361"
    },
    {
      "nct_id": "NCT03885661",
      "title": "Vascepa to Accelerate Lipoprotein Uptake and Elimination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lipid Disorder",
        "Triglycerides High",
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "Icosapent Ethyl 1000 MG [Vascepa]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-01-11",
      "completion_date": "2021-06",
      "has_results": true,
      "last_update_posted_date": "2021-11-11",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03885661"
    },
    {
      "nct_id": "NCT00146211",
      "title": "TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "Ethyl-EPA (Miraxion™)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Neuroscience Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2005-09",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-12-27",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146211"
    },
    {
      "nct_id": "NCT01047501",
      "title": "Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "AMR101 (ethyl icosapentate) - 4 g/day",
          "type": "DRUG"
        },
        {
          "name": "AMR101 (ethyl icosapentate) - 2 g/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 702,
      "start_date": "2009-12",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 80,
      "location_summary": "Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01047501"
    },
    {
      "nct_id": "NCT02422446",
      "title": "Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Icosapent ethyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2015-04",
      "completion_date": "2017-03-01",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422446"
    },
    {
      "nct_id": "NCT02719327",
      "title": "Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "icosapent ethyl (IPE)",
          "type": "DRUG"
        },
        {
          "name": "gel cap placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 131,
      "start_date": "2017-06-08",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02719327"
    },
    {
      "nct_id": "NCT02113163",
      "title": "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Metformin Eicosapentaenoate",
          "type": "DRUG"
        },
        {
          "name": "Metformin HCl and Vascepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thetis Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-10-04T09:53:33.738Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113163"
    }
  ]
}